Several biomarkers, including cell‐of‐origin (COO), the double expression of MYC and BCL2 (double‐expressor lymphoma [DEL]), and MYC and BCL2 rearrangements (double‐hit lymphoma [DHL]), have been identified as adverse prognostic factors for patients with DLBCL.7, 8, 9. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.